Edwin Martinez de Andino, MD
Rheumatology · Aiken, SCNPI 1841261526
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 600 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,264 and has fallen 58.0% since, to $1,369 in 2024.
Across 600 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Pfizer$2K
- AbbVie$1K
- Novartis$881
- Johnson & Johnson$812
- UCB, Inc.$632
- plus $3K from 19 others
What the payments were for
- Food & beverage$10,68799%
- Education$1301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 126 | $2,200 |
| Pfizer | 90 | $1,502 |
| AbbVie(2 entities) | 74 | $1,367 |
| Novartis | 63 | $881 |
| Johnson & Johnson | 35 | $812 |
| UCB, Inc. | 41 | $632 |
| Boehringer Ingelheim | 29 | $556 |
| AstraZeneca(2 entities) | 26 | $542 |
| Lilly USA, LLC | 30 | $497 |
| Radius Health, Inc. | 18 | $327 |
| Sunovion Pharmaceuticals Inc. | 14 | $270 |
| Mallinckrodt Hospital Products Inc. | 9 | $244 |
| GSK | 9 | $213 |
| Regeneron Healthcare Solutions, Inc. | 9 | $196 |
| Bristol Myers Squibb | 6 | $111 |
| E.r. Squibb & Sons, L.L.C. | 4 | $87 |
| Mallinckrodt Enterprises LLC | 3 | $84 |
| Aurinia Pharma U.S., Inc. | 3 | $70 |
| Organon | 3 | $61 |
| Octapharma USA, Inc. | 1 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| Fresenius Kabi USA, LLC | 2 | $36 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Pacira Therapeutics, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
How this compares
$10,817 in reported general payments places this provider in the 65th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 66 | $492,380 |
| OfevNintedanib Esylate | 17 | $235,545 |
| TremfyaGuselkumab | 12 | $168,152 |
| Humira(Cf) PenAdalimumab | 23 | $160,359 |
| Xeljanz XrTofacitinib Citrate | 23 | $128,360 |
| RinvoqUpadacitinib | 11 | $69,152 |
| Orencia ClickjectAbatacept | 11 | $65,244 |
| EliquisApixaban | 242 | $36,103 |
| TrulicityDulaglutide | 49 | $19,507 |
| JanuviaSitagliptin Phosphate | 124 | $17,988 |
| RexultiBrexpiprazole | 25 | $17,368 |
| XareltoRivaroxaban | 106 | $15,474 |
| MethotrexateMethotrexate Sodium | 900 | $14,755 |
| JardianceEmpagliflozin | 52 | $8,039 |
| Hydroxychloroquine Sulfate | 278 | $7,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Jardiance, Tradjenta | $556 | $250,511122 claims |
| Johnson & JohnsonTremfya, Xarelto | $812 | $183,626118 claims |
| AbbVieRinvoq | $1,367 | $69,15211 claims |
| PfizerEliquis | $1,502 | $36,103242 claims |
| Lilly USA, LLCTrulicity | $497 | $19,50749 claims |
| GSKTrelegy Ellipta | $213 | $7,46112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 123 rheumatology providers in South Carolina.
Other rheumatology in Aiken
- Colin EdgertonSummerville$3.5M
- Gregory NiemerSummerville$2.9M
- Gary FinkSummerville$2.9M
- Clarence LegertonSummerville$2.9M
- Jennifer MurphySummerville$2.8M
- William EdwardsSummerville$1.3M
- Alan BrownGreenville$947K
- Douglas ConawayMyrtle Beach$500K
- Long Huynh-DucGreenville$278K
- Robert KeenanFlorence$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.